Drug Profile
Research programme: biosimilars - Eden Biologics
Alternative Names: JHL 1147; JHL 1199; JHL 1211; JHL 1227; Omalizumab biosimilar - Eden Biologics; Pertuzumab biosimilar - Eden BiologicsLatest Information Update: 07 Jun 2023
Price :
$50
*
At a glance
- Originator JHL Biotech
- Developer Eden Biologics; JHL Biotech
- Class Antiallergics; Antiasthmatics; Antineoplastics; Antirheumatics; Eye disorder therapies; Monoclonal antibodies; Osteoporosis therapies; Skin disorder therapies
- Mechanism of Action Dimerisation inhibitors; ERBB 2 receptor antagonists; IgE receptor antagonists; Immunomodulators; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Allergic asthma; Breast cancer; Chronic urticaria; Gastric cancer
- Discontinued Autoimmune disorders; Cystic fibrosis
Most Recent Events
- 31 May 2023 Selexis has merged with KBI Biopharma to form KBI Biopharma
- 28 May 2022 No recent reports of development identified for preclinical development in Allergic-asthma(In adolescents, In children, Treatment-experienced, In adults) in Taiwan (Parenteral)
- 28 May 2022 No recent reports of development identified for preclinical development in Chronic-urticaria(In adolescents, Treatment-experienced, In adults) in Taiwan (Parenteral)